Understanding coronary artery calcification in patients with type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a long-term cohort of patients with type 2 diabetes mellitus (T2DM) who have coronary artery calcification (CAC). It involves a baseline survey followed by an 8-year follow-up across multiple hospitals in Hunan Province, China. The study will evaluate the volume and density of CAC using low dose CT coronary angiography and assess the impact of statins on the progression of CAC. The research seeks to clarify the epidemiological characteristics and clinical progression of CAC in T2DM patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years old
* Type 2 diabetes is diagnosed according to WHO diagnostic criteria
* Low dose prospectively triggered sequential dual-source CT coronary angiography can be performed at baseline investigation
* Those subjects are able to understand the purpose and procedure of this study and sign the informed consent voluntarily

Exclusion Criteria:

* Those have received coronary artery stenting or coronary artery bypass grafting
* Those with severe lung (respiratory failure), liver (ALT or AST 3 times normal value or bilirubin increase), renal dysfunction\[GFR \< 45ml/(min.1.73m2) or dialysis patients
* Malignant tumor
* Mental illness or mental retardation
* Pregnant or lactating women or those with fertility planning
* Concomitant diseases (hyperparathyroidism, sarcoidosis, amyloidosis) affecting calcium balance and soft tissue calcification
* Contraindications of contrast agents
* Based on the judgment of the researcher, the compliance is poor and the study could not be completed according to the requirements

Where it's running

• The First Affiliated Hospital of University of South China
  Hengyang, China Recruiting

Study contacts

• Study coordinator: Liu Jianghua, PhD
• Email: jianghua990@126.com
• Phone: （+86）13407340909

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acute Blood Flow Restriction Walking in Type 2 Diabetes

  This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.

  Recruiting University of British Columbia · Kelowna, British Columbia · NCT07928531

• Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin

  This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.

  Recruiting Medical University of Bialystok · Bialystok · NCT07919236

• Differentiating heart disease in autoimmune vs. type 2 diabetes

  This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.

  Recruiting University of Roma La Sapienza · Rome, Roma · NCT07911007

• Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses

  This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.

  Recruiting at 2 sites German Institute of Human Nutrition · Berlin and 1 other locations · NCT07888257

• Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar

  This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.

  Recruiting German Institute of Human Nutrition · Potsdam, Potsdam-Rehbrücke · NCT07868601

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.